Amanote Research
Register
Sign In
SAT0198 Tocilizumab for the Management of Rheumatoid Arthritis: Discontinuation Due to Inefficacy and Toxicity – Experience From a Large Teaching Hospital
doi 10.1136/annrheumdis-2017-eular.5105
Full Text
Open PDF
Abstract
Available in
full text
Date
June 1, 2017
Authors
E Byrne
P Mark
S Khalid
K-P Kuet
R Kilding
K Graves
J Maxwell
M Akil
Publisher
BMJ Publishing Group Ltd and European League Against Rheumatism
Related search
Acute Anterior Uveitis After Discontinuation of Tocilizumab in a Patient With Rheumatoid Arthritis
Clinical Ophthalmology
Ophthalmology
Immunotherapy of Tocilizumab for Rheumatoid Arthritis
Journal of Clinical & Cellular Immunology
Causes of Synthetic Disease-Modifying Drug Discontinuation in Rheumatoid Arthritis: Data From a Large Real-Life Cohort
PLoS ONE
Multidisciplinary
Cost-Effectiveness Analysis of Tocilizumab Subcutaneouscombotherapy First Line for the Management of Rheumatoid Arthritis in Greece
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Longitudinal Immunomonitoring Following Tocilizumab in Rheumatoid Arthritis
Journal of Translational Medicine
Biochemistry
Medicine
Genetics
Molecular Biology
Pyogenic Arthritis Due to Bacteroides Complicating Rheumatoid Arthritis.
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Tocilizumab, a Humanized Anti-Interleukin-6 Receptor Antibody, for Treatment of Rheumatoid Arthritis
Open Access Rheumatology: Research and Reviews
Rheumatology
Body Mass Index and Clinical Response to Tocilizumab in Patients With Rheumatoid Arthritis
Archives of Rheumatology
Rheumatology
Reasons for Discontinuation of Subcutaneous Biologic Therapy in the Treatment of Rheumatoid Arthritis: A Patient Perspective
Patient Preference and Adherence
Pharmacology
Health Policy
Medicine
Toxicology
Social Sciences
Pharmaceutics
